Argos Therapeutics (ARGSQ) Stock Price, News & Analysis

Company Overview

Argos Therapeutics, Inc. is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, specializing in the development of personalized immunotherapies for oncology and infectious diseases. Founded in 2007, Argos leverages its proprietary RNA‐transfected dendritic cell platform to engineer patient‐specific vaccines designed to stimulate targeted immune responses against cancer cells or chronic viral infections.

The company’s lead product candidate, AGS-003, is an autologous dendritic cell vaccine in development for advanced renal cell carcinoma. Argos has also explored therapeutic programs in chronic hepatitis B and other infectious diseases by adapting its platform to present viral antigens and boost antiviral immunity. Argos Therapeutics has conducted multiple Phase II and Phase III clinical trials in North America and Europe, collaborating with academic institutions and contract research organizations to advance its pipeline.

Argos Therapeutics is led by President and Chief Executive Officer Dr. Laurence J. Reid, supported by a management team with expertise in immunology, cell therapy manufacturing and clinical development. While its primary operations are based in the United States, the company’s clinical trial activities have spanned international sites to access diverse patient populations and regulatory environments. Argos continues to focus on refining its dendritic cell technology and pursuing strategic partnerships to broaden the application of its personalized immunotherapy platform.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.02 to $0.25
• Volume: N/A
• Average Volume: 13,394 shs
• Market Capitalization: $571.70 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARGSQ Stock Analysis - Frequently Asked Questions

How have ARGSQ shares performed this year?

Argos Therapeutics' stock was trading at $0.0540 at the start of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) issued its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analysts' expectations of $0.10 million.

When did Argos Therapeutics' stock split?

Shares of Argos Therapeutics reverse split on Friday, January 19th 2018.The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/09/2017
• Today: 9/16/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ARGSQ
• CIK: 1105533
• Web: www.argostherapeutics.com
• Phone: 919-287-6300
• Fax: N/A
• Employees: 122
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.90 million
• Price / Sales: 0.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.63) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 10,587,000
• Free Float: N/A
• Market Cap: $571.70 thousand
• Optionable: Not Optionable
• Beta: 2.47